CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
Abstract
Breast cancer is the most common cause of death from cancer among women in Russia. More than half of patients have metastases at diagnosis. Chemotherapy is an important component of combined modality treatment for breast cancer. The budget impact analysis of expenses for the use of eribulina demonstrated that its inclusion in the «List of Essential Drugs» greatly expand the possibilities of treatment for metastatic breast cancer without causing significant additional burden on the health budget of the Russian Federation.
About the Authors
S. L. Plavinsky
North-Western State Medical University named after I.I. Mechnikov, St-Petersburg
Russian Federation
Russian Federation
P. I. Shabalkin
Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow
Russian Federation
1, Samora Mashel Street, 117997-Moscow
Russian Federation
1, Samora Mashel Street, 117997-Moscow
References
1. Oncological service for Russian population in 2012 / Eds. A.D. Kaprin, V.V. Starinskij, G.V. Petrova. M., 2013. P. 20–95. [in Russian]
2. Rudakova A.V., Poddubnaja I.V., Zarickij A.Ju., Stadnik E.A. Costeffectiveness of bendamustine in the treatment of indolent non-Hodgkin’s lymphoma // Sovremennaja onkologija. 2011. Vol. 13 (2). P. 26–30. [in Russian]
3. Jagudina R.I., Kulikov A.Ju., Nguen T. Determination of the willingness-to pay-threshold in Russia, European countries and the CIS countries // Farmakojekonomika. 2011. Vol. 4 (1). P. 7–12. [in Russian]
4. Cortes J., O’Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., Chollet P., Manikas A., Diéras V., Delozier T., Vladimirov V., Cardoso F., Koh H., Bougnoux P., Dutcus C.E., Seegobin S., Mir D., Meneses N., Wanders J., Twelves C. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study // Lancet. 2011. Vol. 377 (9769). P. 914–923. doi: 10.1016/S0140-6736(11)60070-6.
5. Dufresne A., Pivot X., Tournigand C., Facchini T., Altweegg T., Chaigneau L., De Gramont A. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer // Breast Cancer Res. Treat. 2008. Vol. 107 (2). P. 275–279.
6. Eichler H.G., Kong S.X., Gerth W.C., Mavros P., Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decisionmaking: how are cost-effectiveness thresholds expected to emerge? // Value Health. 2004. Vol. 7 (5). P. 518–528.
7. Greenhalgh J., Bagust A., Boland A. et al. Eribulin for the treatment of advanced or metastatic breast cancer: A Single Technology Appraisal. Liverpool. The University of Liverpool, 2011. 89 p.
8. Preston J.N., Trivedi M.V. Eribulin: a novel cytotoxic chemotherapy agent // Ann Pharmacother. 2012. Vol. 46, № 6. P. 802–811. doi: 10.1345/ aph.1Q636.
Review
For citations:
Plavinsky S.L., Shabalkin P.I. CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER. Siberian journal of oncology. 2014;(5):17-23. (In Russ.)
Views:
938
Email this article 
